. 2020 May 7;15(11):907–932. doi: 10.1002/cmdc.202000223
© 2020 Wiley‐VCH Verlag GmbH & Co. KGaA, Weinheim
This article is being made freely available through PubMed Central as part of the COVID-19 public health emergency response. It can be used for unrestricted research re-use and analysis in any form or by any means with acknowledgement of the original source, for the duration of the public health emergency.
Figure 20.
Decahydroisoquinolyl‐based SARS‐CoV 3CL pro inhibitors 46–49.